Trial · NCT00628628

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

NCT00628628, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2013-08-01

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Rasburicase in Patients at Risk for Tumor Lysis Syndrome. Trials, record NCT00628628. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00628628

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Rasburicase in Patients at Risk for Tumor Lysis Syndrome
NCT number: NCT00628628
Status: Completed
Phases: Phase 2
Enrollment: 82 participants, actual
Lead sponsor: M.D. Anderson Cancer Center
Conditions: Tumor Lysis Syndrome
Interventions: As Needed Rasburicase, Fixed Dose Rasburicase
First posted: 2008-03-05
Last updated: 2013-08-01
Results first posted: 2013-08-01

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With Plasma Uric Acid (UA) Response	First cycle of chemotherapy, up to 5 days	Plasma UA response is defined as normalization of plasma UA levels within 48 hours after the start of study drug (rasburicase) and maintaining within the normal range after the final drug infusion on day 5. Plasma samples for UA were collected at baseline before rasburicase, 4- and 24-hours post-rasburicase, and daily during treatment.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With Plasma Uric Acid (UA) Response	First cycle of chemotherapy, up to 5 days		participants	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Participants With Plasma Uric Acid (UA) Response	Group A: Single Dose		39		participants
Number of Participants With Plasma Uric Acid (UA) Response	Group B: Daily Dose		34		participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Group A: Single Dose	40
Overall Study	STARTED	Group B: Daily Dose	40
Overall Study	COMPLETED	Group A: Single Dose	40
Overall Study	COMPLETED	Group B: Daily Dose	40
Overall Study	NOT COMPLETED	Group A: Single Dose	0
Overall Study	NOT COMPLETED	Group B: Daily Dose	0

Source ClinicalTrials.gov

Adverse events24

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Methemoglobinemia	Blood and lymphatic system disorders	Group A: Single Dose	0	40
other	Methemoglobinemia	Blood and lymphatic system disorders	Group B: Daily Dose	1	40
other	Hemolysis	Blood and lymphatic system disorders	Group A: Single Dose	1	40
other	Hemolysis	Blood and lymphatic system disorders	Group B: Daily Dose	0	40
other	Clinical tumor lysis syndrome	Metabolism and nutrition disorders	Group A: Single Dose	0	40
other	Clinical tumor lysis syndrome	Metabolism and nutrition disorders	Group B: Daily Dose	3	40
other	Laboratory tumor lysis syndrome	Metabolism and nutrition disorders	Group A: Single Dose	14	40
other	Laboratory tumor lysis syndrome	Metabolism and nutrition disorders	Group B: Daily Dose	11	40
other	Hyperuricemia	Blood and lymphatic system disorders	Group A: Single Dose	13	40
other	Hyperuricemia	Blood and lymphatic system disorders	Group B: Daily Dose	11	40

1 to 10 of 24Source ClinicalTrials.gov

See all 24 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Group A: Single Dose
Total, all-cause mortality	Group B: Daily Dose
Total, other adverse events	Group A: Single Dose	40	40
Total, other adverse events	Group B: Daily Dose	40	40
Total, serious adverse events	Group A: Single Dose	0	40
Total, serious adverse events	Group B: Daily Dose	2	40

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
22015451	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Group A: Single Dose vs Group B: Daily Dose: Number of Participants With Plasma Uric Acid (UA) Response	Trial comparisons
Group A: Single Dose vs Group B: Daily Dose: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00628628

GET https://conductscience.org/api/trials/v1/NCT00628628/events?page=2

API reference For AI assistants